Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -86.1% | 185.6% | – | – |
| Cost of Goods Sold | $90 | $0 | $0 | $0 |
| Gross Profit | -$90 | $1 | $0 | $0 |
| % Margin | -63,161.5% | 100% | 100% | – |
| R&D Expenses | $90 | $80 | $76 | $67 |
| G&A Expenses | $52 | $50 | $36 | $28 |
| SG&A Expenses | $52 | $50 | $36 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$90 | $0 | $0 | $0 |
| Operating Expenses | $52 | $130 | $112 | $95 |
| Operating Income | -$143 | -$129 | -$111 | -$95 |
| % Margin | -99,710.5% | -12,523% | -30,860.1% | – |
| Other Income/Exp. Net | $12 | $13 | $15 | $14 |
| Pre-Tax Income | -$130 | -$116 | -$97 | -$81 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$130 | -$116 | -$97 | -$81 |
| % Margin | -90,972.7% | -11,216% | -26,807.2% | – |
| EPS | -1.38 | -1.23 | -1.04 | -0.88 |
| % Growth | -12.2% | -18.3% | -18.2% | – |
| EPS Diluted | -1.38 | -1.23 | -1.04 | -0.88 |
| Weighted Avg Shares Out | 94 | 94 | 93 | 91 |
| Weighted Avg Shares Out Dil | 94 | 94 | 93 | 91 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $13 | $15 | $14 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$129 | -$128 | -$110 | -$94 |
| % Margin | -90,265% | -12,430% | -30,603.9% | – |